Pneumagen is developing a glycan targeted intranasally delivered therapy for the pan-viral, universal treatment of infectious diseases of the respiratory tract

Latest news

21 Jan, 2021
Pneumagen Announces £2.5m fundraising to advance universal treatment for viral respiratory infections into the clinic this year
05 Oct, 2020
Pneumagen’s Neumifil for combating COVID-19 featured in SCRIP’s 10 to watch at BIO-Europe Digital
16 Sep, 2020
Pneumagen Announces Scientific Advisory Board and Development Team Appointments

Meet the team